COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review
Abstract Immunosuppressed patients have increased risk for morbidity and mortality from COVID-19 because they less frequently mount antibody responses to vaccines and often cannot tolerate small- molecule antivirals. The Omicron variant of concern of SARS-CoV-2 has progressively defeated anti-Spike mAbs authorized so far, paving the way to a return to COVID-19 convalescent plasma (CCP) therapy. In this systematic review we performed a metanalysis of 8 controlled studies (totaling 469 treated patients and 1305 controls and including 3 randomized controlled trials), an individual patient data analysis of 125 case reports/series (totaling 265 patients), and a descriptive analysis of 13 uncontrolled large case series without individual patient data available (totaling 358 patients). The metanalysis of controlled studies showed a risk ratio for mortality of 0.63 (0.58 in randomized controlled trials) in treatment with CCP versus standard of care for immunosuppressed COVID-19 patients. On the basis of this evidence, we encourage initiation of high-titer CCP from vaccinees (‘hybrid plasma’) in immunocompromised patients.
Cruciani Mario、K.Gorman Ellen、Focosi Daniele、Casadevall Arturo、Mengoli Carlo、Senefeld Jonathon W.、Joyner Michael J、Franchini Massimo、Zani Matteo
Division of Transfusion Medicine, Carlo Poma HospitalDepartment of Anesthesiology and Perioperative Medicine, Mayo ClinicNorth-Western Tuscany Blood Bank, Pisa University HospitalDepartment of Medicine, Johns Hopkins School of Public Health and School of MedicineDivision of Transfusion Medicine, Carlo Poma HospitalDepartment of Anesthesiology and Perioperative Medicine, Mayo ClinicDepartment of Anesthesiology and Perioperative Medicine, Mayo ClinicDivision of Transfusion Medicine, Carlo Poma HospitalDivision of Transfusion Medicine, Carlo Poma Hospital
医学研究方法临床医学内科学
convalescent plasmaCOVID-19SARS-CoV-2immunosuppression
Cruciani Mario,K.Gorman Ellen,Focosi Daniele,Casadevall Arturo,Mengoli Carlo,Senefeld Jonathon W.,Joyner Michael J,Franchini Massimo,Zani Matteo.COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review[EB/OL].(2025-03-28)[2025-08-26].https://www.medrxiv.org/content/10.1101/2022.08.03.22278359.点此复制
评论